Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | LXH 254 |
Trade Name | |
Synonyms | LXH254|LXH-254|Naporafenib |
Drug Descriptions |
LXH 254 is a RAF inhibitor that selectively inhibits monomeric and dimerized BRAF and CRAF, which may lead to anti-tumor activity in RAF-mutant tumors and better tolerability (AACR Annual Meeting 2019, Abstract LB-114, PMID: 31059256). |
DrugClasses | BRAF Inhibitor 25 CRAF Inhibitor 12 |
CAS Registry Number | 1800398-38-2 |
NCIT ID | C125003 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Dabrafenib + LTT462 + LXH 254 | Dabrafenib LTT462 LXH 254 | 0 | 1 |
Dabrafenib + LXH 254 + Trametinib | Dabrafenib LXH 254 Trametinib | 2 | 0 |
LTT462 + LXH 254 | LTT462 LXH 254 | 4 | 2 |
LXH 254 | LXH 254 | 18 | 1 |
LXH 254 + Nazartinib | LXH 254 Nazartinib | 0 | 1 |
LXH 254 + Ribociclib | LXH 254 Ribociclib | 0 | 1 |
LXH 254 + SHP099 | LXH 254 SHP099 | 0 | 0 |
LXH 254 + Sotorasib | LXH 254 Sotorasib | 0 | 0 |
LXH 254 + Spartalizumab | LXH 254 Spartalizumab | 0 | 1 |
LXH 254 + Trametinib | LXH 254 Trametinib | 5 | 3 |